A Feasibility Study of Topical Cannabinoids for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in Adults With Hormone Receptor-Positive Breast Cancer (CanAroma)

Early Phase 1

Completed

• Conditions: Musculoskeletal Syndrome
• Interventions: Drug: CBD-dominant; Drug: THC dominant

• Registration Number: NCT05935891
• Lead Sponsor: University of Minnesota

Brief Summary

Aromatase inhibitors (AIs) are commonly used for post-menopausal women with hormone-positive breast cancer. Compared to tamoxifen, AIs improve breast cancer recurrence rates and lower 10-year breast cancer mortality. Unfortunately, nearly 2 out of 3 women with estrogen-receptor positive breast cancer treated with AIs experiences AIMSS, such as arthralgia, joint stiffness, and bone pain, and 30% of women with AIMSS report severe pain. AIMSS leads to poor adherence with therapy and discontinuation of therapy in up to 20% of patients. Despite the large number of women affected, current therapeutic interventions have shown only limited efficacy in improving AIMSS. Therefore, the presence of AIMSS may negatively impact breast cancer recurrence and survival. In this current trial, the plan is to utilize topical cannabinoid creams from Vireo Health that have been tested for potency and purity. Two distinct products with different THC/CBD ratios will be provided to patients at no cost; a) a THC-dominant cream (Red XS Balm with 375mg/jar and \<20mg of CBD) and b) a CBD-dominant cream (Violet Balm with 2210mg CBD/jar and \<0.3% THC). The study will explore the feasibility of doing larger, placebo controlled trials by first ensuring adequate patient interest, acceptable tolerability/safety of cream utilization, and preliminary efficacy measures. All patients completing assessments through day 14 will be allowed to choose either Red XS or Violet creams for an additional 2-week extension period.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-02-09
• Study First Submitted: 2023-06-15
• Study First Submitted QC: 2023-06-28
• Study First Posted: 2023-07-07
• Primary Completion: 2024-04-29
• Study Completion: 2024-04-29
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-02
• Last Update Posted: 2025-04-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

• Age 18 years or above at the time of signing the informed consent form.
• Histologically proven diagnosis of stage I-III invasive breast cancer.
• Currently taking prescribed dose of an aromatase inhibitor (e.g., anastrazole, letrozole, exemestane) for at least 60 days with a plan to continue for at least 4 weeks after time of consent.
• Initiated AI therapy must have been within 48 months at time of consent.
• Experiencing AIMSS in hands and/or wrists for at least 4 weeks prior to time of consent.
• Patients must have reported a score of 4 or higher on at least one of the four M-SACRAH questions regarding pain and stiffness in hands and/or wrists over the past 7 days. Patients experiencing AIMSS symptoms in other joints are eligible, but must have pain in hands and/or wrists.
• Must be willing and able to comply with study visits and procedures.
• Must be willing to be registered in the Minnesota Medical Cannabis Program (MMCP).
• Must meet qualifications for the Minnesota Medical Cannabis

Program (MMCP). This includes:

1. Must have a qualifying condition, as per MMCP requirements, that is certified by a Health Care Practitioner.
2. Must be a Minnesota resident.

Exclusion Criteria

• The patient is currently using or has used cannabinoids within 4 weeks of time of consent.
• Active skin lesions on hands/wrists that the investigator feels could impair absorption of cannabinoid cream or lead to increased toxicity (e.g., psoriasis, cellulitis, cutaneous lupus erythematosus, hand-foot syndrome).
• Plan to start or increase doses of other analgesics aimed at improving AIMSS symptoms (e.g., duloxetine, non-steroidal anti- inflammatories, acetaminophen, opioids). Of note, patients are eligible if they have remained on stable doses of AIMSS related medications for 4 weeks prior to time of consent and do not plan to escalate the dose.
• Current or planned initiation of acupuncture to arms, wrists or hands within study period.
• Any known or suspected hypersensitivity to topical cannabinoids.
• Any condition that the investigator believes would interfere with the ability to provide informed consent, comply with the study protocol, or would put the subject at undue risk.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Violet	CBD-dominant	Patients receiving CBD-dominant balm
Red Xs	THC dominant	Patients receiving THC-dominant balm

Primary Outcome Measures

Name	Time	Method
subject retention rate	4 weeks	percentage of participants who completed the study
subject recruitment rate	4 weeks	percentage of participants actually recruited out of anticipated

Secondary Outcome Measures

Name	Time	Method
change in Brief Pain Inventory Short Form (BPI-SF) scores	2 weeks and 4 weeks	worst pain, average pain, pain interference with general activity minimum value is zero equals no pain and maximum value is 10 equals pain as bad as you can imagine and the higher the score the worse the outcome.
tolerability of topical medical cannabis creams	2 weeks and 4 weeks	documenting patient adherence to dosing protocol through a Patient Topical Cannabis Dosing Diary.; This is a document where the patient records the date, time, to which hands the dose was applied and if the dose was missed.

Trial Locations

Locations (1)

University of Minnesota; 🇺🇸 Minneapolis, Minnesota, United States